BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma by CHIAPPETTA, CATERINA et al.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
BRAF and NRAS Mutations are Heterogeneous and Not
Mutually Exclusive in Nodular Melanoma
Caterina Chiappetta, BS,* Ilaria Proietti, MD,w Valentina Soccodato, MD,w
Chiara Puggioni, PhD,* Roberto Zaralli, PhD,* Luca Pacini, PhD,* Natale Porta, MD,*
Nevena Skroza, MD,w Vincenzo Petrozza, MD,* Concetta Potenza, MD,w Carlo Della Rocca, MD,*
and Claudio Di Cristofano, MD*
Abstract: Inhibitors of RAF inhibit the MAPK pathway that plays
an important role in the development and progression of those
melanoma carrying the V600E BRAF mutation, but there’s a
subset of such patients who do not respond to the therapy. Various
mechanisms of drug resistance have been proposed which include
the clonal heterogeneity of the tumor. We have studied a pop-
ulation of nodular melanoma to investigate the intratumor and
intertumor heterogeneity by Laser Capture Microdissection (LCM)
analysis. Our results showed that BRAF andNRASmutations were
detected in 47% and 33% of nodular melanoma, respectively, and
that there is a discrepancy in mutational pattern of tumoral sample
because in the 36% of patients a different mutation, in at least 1
area of the tumor, was found by LCM analysis, giving evidence of
the presence of different clonal cells populations. Moreover, we
found that mutations in BRAF and NRAS are not mutually ex-
clusive because they were simultaneously present in the same tumor
specimens and we observed that when the 2 different mutations
were present one is a high-frequency mutation and the other is a
low-frequency mutation. This was more evident in lymphonodal
metastasis that resulted from wild type to mutational analysis, but
showed different mutations following LCM analysis. Therefore, we
believed that, when primary tumoral sample results negative to
mutational analysis, if it is possible, metastases should be inves-
tigated to verify the presence of mutations. Generally, it should be
searched for other mutations, in addition to BRAF V600E, so as to
better understand the mechanism of drug resistance.
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Nodular melanoma is the second commonest subtypeafter superficial spreading melanoma, and it com-
prises 20% to 25% of cutaneous melanoma cases.1–3 The
V600E mutation (Val600Glu) accounts for over 90% of all
BRAF mutations detected in cutaneous melanoma, whereas
the most common NRAS mutation in cutaneous melanoma
are the Q61R (Glut61Arg) and Q61K (Glut61Lys); these
mutations result in activation of the downstream effector of
the RAS-RAF-MEK-MAPK pathway.4 This pathway is
important in several crucial processes, such as proliferation
and differentiation.3 Inhibitors of BRAF (vemurafenib and
debrafenib) have been developed and have shown clinical
benefits, such as response rate, progression-free survival, and
overall survival, compared with chemotherapy treatments in
patients with BRAFmutated metastatic melanoma.5 Despite
this advances, the great majority of patients treated with
these drugs have developed disease progression within 6 to 7
months after the initiation of the treatment.5–7 The mecha-
nisms of resistance are multiples and include the reactivation
of alternative signaling pathway as well as MAPK pathway
involvement5–7 through different ways like the development
of an NRAS mutation.8 Recent results indicate that it is not
possible to think of an effective therapeutic strategy or of a
more sensitive and specific evaluation of malignant tumors
without taking into account more molecular parameters5–7;
in fact, the acquisition of multiple genomic alterations can
cause the formation of different subclones in the same tumor
or in the primitive and metastatic localization resulting in
intratumor and intertumor heterogeneity in a single patient;
it was hypothesized that this process could be one of the
mechanism causing resistance to the drug.9 A better under-
standing of intratumor and intertumor heterogeneity is es-
sential to advance the effect of molecular diagnostics in
determining therapeutic strategies. In this study, we analyzed
a population of nodular melanoma tumor specimens to de-
tect mutations in BRAF and NRAS using Laser Capture
Microdissection (LCM) and investigating in such way the
intratumor heterogeneity to define the presence of different
clonal population of tumor cells.
MATERIALS AND METHODS
Population Study
The population of this study included 15 patients with
nodular melanoma, 9 men and 6 women, with median age
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of 71 years (range, 23 to 92y). We chose this histologic type
of melanoma because in this study we needed rich tissue
samples to make molecular analysis by LCM. The samples
were collected from the files of the Pathology Unit of the
Latina Local Health Unit at I.C.O.T hospital. The WHO
2008 classification of cutaneous melanoma was used to
classify the lesions. Median tumor size was 2.3mm (range, 1
to 6mm); of the 15 patients, 2 (13.5%) were of Clark level
III, 11 (73%) were of Clark level IV, and 2 (13.5%) were of
Clark level V. The Breslow thickness ranged from 1.6 to
12mm with a mean of 7.1mm. The majority of patients
(10/15, 66.7%) presented ulceration and the mean value of
mitotic index was 7. Twelve patients presented regression
area (80%, 12/15), 13 patients (87%) showed tumor-in-
filtrating lymphocytes, and only one of these was in the
brisk category (1/13, 8%). Eleven patients underwent sen-
tinel lymph node biopsy and only 1 resulted positive (1/15;
6%). Four patients did not undergo to sentinel lymph node
biopsy because they presented obvious metastasis by image
analysis techniques. The tumor stage was IIC in 6/15
(40%), IIB in 3/15 (20%), IIA in 1/15 (6%), IIIB in 1/15
(6%), and IV in 4/15 (27%). Immunoistochemical analysis
of S100, HMB45, MART1, and Melan A were performed
in each case to confirm the morphologic and clinical diag-
noses. The mean value of the proliferation index evaluated
by Ki67 was 14.7%. Median follow-up was 31 months
(range, 12 to 60mo) and 7/15 (47%) patients died.
Mutation Analysis
Tumor tissue samples were analyzed for both BRAF
(NCBI Gene ID, 673) and NRAS (NCBI Gene ID, 4893)
gene mutations by direct sequencing analysis of exons 11
and 15 of the BRAF gene and exons 1 and 2 of the NRAS
gene. Representative tumor tissue sections (>80% tumor
cells) were cut (10 mm thick) and placed directly into a
sterile tube. DNA was extracted using Wizard SV
Genomic DNA Purification System (Promega, Madison,
CA). DNAs were amplified in a final volume of 50 mL
containing 30 ng of DNA, 2mM dNTP, 250 ng/mL of
each primer, 1.5mM MgCl2, 1 PCR buffer, and 1U
HotStartGoTaq Polymerase (Promega). A total of 40
cycles were performed using the Gene Amp PCR System
9700 (Life Technologies, Foster City, CA) at 951C for 45
seconds, specific annealing temperature for 45 seconds,
721C for 1 minute. The PCR products were then purified
using Exosap-IT (Affymetrix, Santa Clara, CA) and then
sequenced using Big Dye Terminator version 1.1 Cycle
Sequencing Kit (Life Technologies). Unincorporated
primers and dye terminators were removed using the
Montage-SEQ96 Sequencing Reaction Cleanup Kit
(Merck Millipore, Billerica, MA). Sequencing was per-
formed on an ABI PRISM 3100 Genetic Analyzer (Life
Technologies) with 3100 Genetic Analyzer Data Collec-
tion software version 1.1. The sequencing and each re-
action were performed in triplicate.
LCM to Analyze Intratumor Heterogeneity
We used LCM to isolate 3 areas of 10,000 tumor
cells from each of 15 melanoma tumor specimens. For
microdissection by Leica LMD 7000 (Leica Micro-
systems, MI, Italy), 5-mm-thick sections were performed
on specific glasses with thermoplastic membrane activated
by a low-energy infrared laser pulse and stained with
hematoxylin and eosin. The selected tissue fragments were
harvested by simple lifting of the cap, which was then
transferred to a microcentrifuge tube containing the
buffer solutions required for the isolation of the DNA.
Total DNA from the microdissected tissue was extracted
by using DNA extraction buffer (Tris-HCl pH 8: 100mM;
EDTA: 1mM; Tween-20: 1%; Proteinase K: 200 to
300 mg/mL) and incubated at 371C for 16 hours. The re-
action was then inactivated at 951C for 20 minutes. The
DNA was stored at 201C until it was used. Each dis-
sected tumor sample was evaluated for selective analysis
of BRAF and NRAS mutations via sequencing.
RESULTS
Mutations Analysis
We detected mutations in 11/15 (73%) cases; 6 pa-
tients (54%, 6/11) showed mutations in exon 15 of BRAF,
only 1 patient showed a mutation in exon 11 of BRAF
(9%, 1/11); the substitution at codon 600 accounted for
71% (5/7) of BRAF mutations and 3 of these were rep-
resented by the valine to glutamic acid substitution
(V600E, 60%, 3/5). Five patients (45%, 5/11) revealed
mutations in NRAS, only 1 in exon 1 (20%, 1/5) and 4 in
exon 2 (80%, 4/5), specifically a glutamine to leucine/
arginine/lysine substitution at position 61 (Q61L/R/K).
In a same tumor specimen we found mutations in BRAF
and NRAS, in particular the substitution at position 467
of serine in leucine in exon 11 of BRAF and the sub-
stitution at position 61 of glutamine in arginine in exon 2
of NRAS. Four patients (27%, 4/15) did not have mu-
tation in either BRAF or NRAS and were referred to as
wild type (WT).
Mutations Analysis by LCM
We analyzed the 3 microdissected areas of each
tumor sample to determine whether they contained a
mixture of subclones characterized by a different muta-
tional status. We found that 7/11 (64%) mutated patients
showed the same mutation found by mutational analysis
without LCM in at least 1 area. Only 4 patients (57%,
4/7) showed the same mutation in all 3 areas, specifically
V600E in exon 15 of BRAF in 2 patients and the glycine
to arginine substitution at position 13 of NRAS exon 1
(G13R) in the third patient; the patient that showed 2
different mutations in the same tumor specimen revealed
this characteristic through the LCM analysis in all 3 areas
too (S467L BRAF exon 11 and Q61R NRAS exon
2, Fig. 1A). Two patients (29%, 2/7) showed the same
mutation in 2 areas: the lysine to glutamic acid sub-
stitution at position 601 of BRAF exon 15 (K601E) and
the other showed the substitution of valine in arginine in
exon 15 of BRAF (V600R) while 1 area resulting WT.
Only 1 patient (14%, 1/7) showed the same mutation in 1
area, the valine to lysine substitution at position 600 of
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BRAF exon 15 (V600K), whereas the other areas resulted
WT. Four patients (36%, 4/11) revealed a different mu-
tational status in at least 1 area compared with muta-
tional analysis without LCM: 1 patient (25%, 1/4)
showed the same mutation in 2 areas (V600E in exon 15
of BRAF) and another mutation (V600R) in the same
exon in the third area; 2 patients (50%, 2/4) showed the
same mutation in all 3 areas (Q61R and Q61K) and also
other mutations in BRAF exon 15, in particular the first
showed the V600R mutation and the alanine to valine
substitution at position 598 (A598V, Fig. 1B) and the last
showed the isoleucine to valine substitution at position
592 (I592V); another patient (25%, 1/4) showed the same
mutation in 2 areas (Q61L) and also revealed the glycine
FIGURE 1. Sequencing electropherograms of the regions of BRAF exons 11 and 15 and NRAS exons 1 and 2. In each line, the first
electropherogram corresponds to the tumoral sample, the other 3 electropherograms correspond to the 3 areas of the micro-
dissected tumor. A, Patient that shows the same 2 mutations of tumor sample (S467L of BRAF exon 11, Q61R of NRAS exon 2) in
all 3 areas; (B) patient that shows the same mutation found in tumoral sample in all 3 areas (Q61R of NRAS exon 2) and also other
2 mutation in 2 different areas (A598V and V600R on BRAF exon 15, respectively); (C) patient that shows the V600E mutation of
BRAF exon 15 in all 3 areas while the tumoral sample is referred to as wild type (WT).
Appl Immunohistochem Mol Morphol  Volume 00, Number 00, ’’ 2014 Mutations Not Mutually Exclusive in Melanoma
r 2014 Lippincott Williams & Wilkins www.appliedimmunohist.com | 3
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
FIGURE 2. Sequencing electropherograms of the LCM areas that show mutations in BRAF exons 11 and 15 and NRAS exons 1
and 2 of metastatic samples. In each line, the first electropherogram corresponds to the metastatic sample, the other 3 elec-
tropherograms correspond to the 3 areas of the microdissected metastasis. A, Metastatic sample that shows the V590I mutation of
BRAF exon 15 in 1 area; (B) metastatic sample that shows the V600E mutation of BRAF exon 15 in 2 areas and the S614P mutation
of BRAF exon 15 also in area 2; (C) metastatic sample that shows the V600E mutation of BRAF exon 15 only in 1 area; (D)
metastatic sample that shows 2 different mutation in 2 different areas, G469R of BRAF exon 11 and G13R of NRAS exon 1.
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to arginine substitution at position 455 of BRAF exon 11
(G455R). In the group referred to as WT, only 1 patient
(1/4, 25%) showed a V600E mutation in all 3 areas
(Fig. 1C). The last 3 patients (3/4, 75%) were also referred
to as WT by LCM analysis.
One patient, male, 59 years old, referred as WT in
primary tumor specimens and by LCM analysis, showed
6 lymph nodal metastasis (LGH); their mutational anal-
ysis did not show mutations, whereas by the LCM anal-
ysis we found a different mutational status in 4/6 (67%)
LGH:
 I LGH: revealed V600E in exon 15 of BRAF in 1 area;
 II LGH: showed the valine to isoleucine substitution at
position 590 of BRAF exon 15 (V590I) in 1 area;
 III LGH: 2 different mutations were revealed in the
same area: the serine to proline substitution at position
614 (S614P) and the V600E mutation in exon 15 of
BRAF; moreover, this showed the V600E mutation in
another area;
 IV LGH: mutations in BRAF and NRAS were revealed
in 2 different areas, specially the glycine to arginine
substitution at position 469 of BRAF exon 11 and the
G13R mutation in exon 1 of NRAS;
 V LGH: referred as WT;
 VI LGH: referred as WT (Fig. 2).
DISCUSSION
The RAS/RAF/MEK/ERK pathway has been re-
ported to be activated in over 90% of all cutaneous
melanomas, and BRAF and NRAS mutations were
studied to understand the mechanisms responsible for
oncogenesis10,11 and to provide new therapeutic strategies
for this deadly disease.12,13
In this study, the frequency of BRAF and NRAS
mutations (47%/33%) was consistent with that reported
in previous studies in which BRAF mutation ranged from
22% to 72% and NRAS mutation ranged from 0% to
50%4,14,15 and, in agreement with the literature, the ma-
jority of BRAF mutations were in codon 600.14,16–19
Surprisingly, 1 patient showed 2 different mutations,
1 in BRAF exon 11 (S467L) and the other in NRAS exon 2
(Q61R) showing that these mutations are not mutually
exclusive as previously stated13; moreover, we confirmed
this result founding both mutations in all 3 areas of the
same tumor, selected with LCM (Fig. 1A). Through LCM
analysis, we found a discrepancy in the mutation pattern
because the 36% of patients revealed a different mutational
status in at least 1 area and even if these mutations have
been already reported in literature the frequency appeared
to be lower.20–22 Finally, in WT group 1 patient (27%)
showed mutations in at least 1 area.
Difference in mutational status was more evident in
the analysis of lymph nodal metastasis of a patient; in-
deed, 4/6 lymph nodal metastasis showed a different
mutational pattern from each other and from the primi-
tive sample. Particularly, one of them presented 2 differ-
ent mutations in the same area, the V600E and the less
well-known S614P mutation giving evidence of the
intratumor and intertumor heterogeneity as already
argued.13,16,17,23
BRAF-targeted therapies showed important results
in therapy for melanoma with activating BRAF V600E
mutations, but mechanisms of intrinsic and acquired drug
resistance have been observed. Our results showed that a
second mutation can be present in the same patients and
it was postulated that the acquisition of other mutations
could be the cause of the MAPK pathway reactivation
and tumor progression.8,24 As well known, the inves-
tigation of V600E mutation to refer patients to the
treatment with inhibitors of BRAF is carried out rou-
tinely on the primary tumor; our results suggest that if the
primary sample is negative for mutation V600E and the
metastatic samples are available, it can be useful also to
perform this mutational analysis on the metastatic sam-
ples, to give the patient another chance to be eligible for
the treatment with inhibitors of BRAF.
We further found that, besides the most frequent
mutations BRAF V600E and NRAS Q61R/K,3,4,25–27
there are also other mutations that should be investigated.
Often, less frequent mutations are not found because the
new methods of mutational analysis are more sensitive but
only for the identification of specific known muta-
tions9,28,29 or because the same exons of a gene are not
always investigated in different studies.15,30 Our results
show that the mutations are not mutually exclusive in
nodular melanomas, indeed we found BRAF and NRAS
mutations in the same sample; however, we hypothesize
that the most frequent mutations could be mutually ex-
clusive, in fact in this study in the case in which 2 different
mutations were present, one of these was a high-frequency
mutation and the other was a low frequency one.
The mechanism by which the other mutations can
participate in the oncogenetic process was not clarified
yet.13 Further studies are needed to confirm these
preliminary results in larger population and it is im-
portant to expand the panel of mutations to be inves-
tigated including genetic and clinical information in better
understanding the mechanisms of drug resistance in
melanoma. For these reasons, it is necessary that muta-
tional analysis is performed with more sensitive methods
such as the whole-genome sequencing.
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17. Heinzerling L, Baiter M, Kühnapfel S, et al. Mutation landscape in
melanoma patients clinical implications of heterogeneity of BRAF
mutations. Br J Cancer. 2013;109:2833–2841.
18. Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of
BRAF mutations in a retrospective, single-institution study of 1112
cases of melanoma. J Mol Diagn. 2013;15:220–226.
19. Schoenewolf NL, Dummer R, Mihic-Probst D, et al. Detecting
BRAF mutations in formalin-fixed melanoma: experiences with two
state-of-the-art techniques. Case Rep Oncol. 2012;5:280–289.
20. Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and
early-life ambient UV exposure are associated with BRAF-mutant
melanoma. Cancer Epidemiol Biomarkers Prev. 2007;16:991–997.
21. Tetsu O, Phuchareon J, Chou A, et al. Mutations in the c-Kit gene
disrupt mitogen-activated protein kinase signaling during tumor
development in adenoid cystic carcinoma of the salivary glands.
Neoplasia. 2010;12:708–717.
22. Akslen LA, Puntervoll H, Bachmann IM, et al. Mutation analysis of
the EGFR-NRAS-BRAF pathway in melanomas from black
Africans and other subgroups of cutaneous melanoma. Melanoma
Res. 2008;18:29–35.
23. Lin J, Goto Y, Murata H, et al. Polyclonality of BRAF mutations in
primary melanoma and the selection of mutant alleles during
progression. Br J Cancer. 2011;104:464–468.
24. Le K, Blomain ES, Rodeck U, et al. Selective RAF inhibitor impairs
ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-
resistant melanoma cells. Pigment Cell Melanoma Res. 2013;26:509–517.
25. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma;
a review of NRAS and BRAF mutation frequencies in relation to
histogenetic subclass and body site. Mol Oncol. 2008;1:395–405.
26. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations
in BRAF, NRAS, and PTEN in primary coutaneous melanoma.
J Invest Dermatol. 2006;126:154–160.
27. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS
mutations in melanoma and melanocytic nevi. Melanoma Res.
2006;16:267–273.
28. Richter A, Grieu F, Carrello A, et al. A multisite blinded study for
the detection of BRAF mutations in formalin-fixed, paraffin-
embedded malignant melanoma. Sci Rep. 2013;3:1659–1667.
29. Machnicki MM, Glodkowska-Mrowka E, Lewandowski T, et al.
ARMS-PCR for detection of BRAF V600E hotspot mutation in
comparison with real-time PCR-based techniques. Acta Biochim Pol.
2013;60:57–64.
30. Bucheit AD, Syklawer E, Jakob JA, et al. Clinical characteristics
and outcomes with specific BRAF and NRAS mutations in patients
with metastatic melanoma. Cancer. 2013;119:3821–3829.
Chiappetta et al Appl Immunohistochem Mol Morphol  Volume 00, Number 00, ’’ 2014
6 | www.appliedimmunohist.com r 2014 Lippincott Williams & Wilkins
